Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGM | P11217 | 3/20 | 0.77 |
| ▸ | TK1 | P04183 | 2/20 | 0.58 |
| ▸ | TK2 | O00142 | 2/20 | 0.55 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.52 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.52 |
| ▸ | CDA | P32320 | 1/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.47 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.47 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.47 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fialuridine SCHEMBL1533997 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL3084377 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL13702050 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL3084382 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL9059414 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL24359134 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL768344 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL773510 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL20769829 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 | |
| Fialuridine SCHEMBL12658448 | 1.00 | PYGM (0.77) | PYGMTK1TK2P2RY6P2RY14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116514888-A | Fluorescent probe and preparation method and application thereof | 深圳大学 | 2023-08-01 | — | — | CN | claimed |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-06-01 | — | — | US | claimed |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-07-30 | — | — | US | claimed |
| WO-2019195494-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIS OF PHOSPHORYLATED MOLECULES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-10-10 | — | — | WO | claimed |
| EP-3423473-A2 | VIRUS VECTORS EXPRESSING MULTIPLE EPITOPES OF TUMOR ASSOCIATED ANTIGENS FOR INDUCING ANTITUMOR IMMUNITY | New York University (US) | 2019-01-09 | — | — | EP | claimed |
| WO-2018161092-A1 | INDUCTION AND ENHANCEMENT OF ANTITUMOR IMMUNITY INVOLVING VIRUS VECTORS EXPRESSING MULTIPLE EPITOPES OF TUMOR ASSOCIATED ANTIGENS AND IMMUNE CHECKPOINT INHIBITORS OR PROTEINS | NEW YORK UNIVERSITY (US) | 2018-09-07 | — | — | WO | claimed |
| US-20180000912-A1 | Virus Vectors Expressing Multiple Epitopes of Tumor Associated Antigens For Inducing Antitumor Immunity | NEW YORK UNIVERSITY | 2018-01-04 | — | — | US | claimed |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | ZGENE A/S (DK) | 2007-11-15 | — | — | US | claimed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | claimed |
| US-20040072168-A1 | Novel deoxynucleoside kinase enzyme variants | KNECHT WOLFGANG (SE) | 2004-04-15 | — | — | US | claimed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | claimed |
| US-20030228285-A1 | Bipartite T-cell factor (Tcf)-responsive promoter | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2003-12-11 | — | — | US | claimed |
| EP-1283874-A2 | NOVEL DEOXYNUCLEOSIDE KINASE ENZYME VARIANTS | Knecht, Wolfgang (DK) | 2003-02-19 | — | — | EP | claimed |
| WO-2001088106-A2 | NOVEL DEOXYRIBONUCLESIDE KINASE ENZYME MULTI-SUBSTRATE VARIANTS | KNECHT WOLFGANG (DK) | 2001-11-22 | — | — | WO | claimed |
| EP-0010205-B1 | 5-SUBSTITUTED 1-(2'-DEOXY-2'-SUBSTITUTED-BETA-D-ARABINOFURANOSYL) PYRIMIDINE NUCLEOSIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Sloan-Kettering Institute For Cancer Research (US) | 1983-05-04 | — | — | EP | claimed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | claimed |
| EP-0010205-A1 | 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them | Sloan-Kettering Institute For Cancer Research (US) | 1980-04-30 | — | — | EP | claimed |
| WO-2026106956-A1 | DISULFIDE-STABILIZED NOROVIRUS VIRUS-LIKE PARTICLE DESIGN | MERCK SHARP & DOHME LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| US-4211773-A | VIRICIDES, ANTITUMOR AGENTS | SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH (US) | 1980-07-08 | — | — | US | disclosed |
| EP-0010205-A1 | 5-Substituted 1-(2'-deoxy-2'-substituted-beta-D-arabinofuranosyl) pyrimidine nucleosides and pharmaceutical compositions containing them | Sloan-Kettering Institute For Cancer Research (US) | 1980-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | PYGM 590/4885TK1 62/4885TK2 207/4885 |
| US-20200239500-A1 | Compositions and Methods for Synthesis of Phosphorylated Molecules | PIK3CA, CHAMP1, TYMP | PYGM 173/4885TK1 22/4885TK2 68/4885 |
| US-20070264241-A1 | Compounds for Enhanced Cancer Therapy | TYMP, BAD, NUDT1 | PYGM 694/4885TK1 16/4885TK2 8/4885 |
| US-11021497-B2 | Compositions and methods for synthesis of phosphorylated molecules | PIK3CA, CHAMP1, TYMP | PYGM 173/4885TK1 22/4885TK2 68/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | PYGM 590/4885TK1 62/4885TK2 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.